Biblography
Our searchable, sortable bibliography is the most comprehensive listing of articles, posters, abstracts, and CME programs on biologic therapy in psoriasis available on the Web. Links to these documents are provided where possible.
A Ammoury, F El Sayed, R Dhaybi, et al. Palmoplantar pustulosis should not be considered as a variant of psoriasisJ Eur Acad Dermatol Venereol. 2007
Date Published: July 2007
Keywords: View Abstract
Abramovits W. Raptiva (efalizumab).SKINmed. 2004;3:37-38.
Date Published: January 2004
Keywords: antigens, CD11a, efalizumab, monoclonal antibodies, psoriasis View Abstract
Abramovits W, Gupta AK. New therapy update: Enbrel (etanercept).SKINmed. 2004;3:333-335.
Date Published: November 2004
Keywords: administration, adverse effects, biological response modifiers, dose-response, etanercept, immunoglobulin G, psoriasis, psoriatic arthritis, receptors, T cells, tumor necrosis factor (TNF) View Abstract
Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics. 2008;26:121-9
Date Published: January 2008
Keywords: View Abstract
Adisen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents.Clin Exp Dermatol. 2008;33:164-6
Date Published: March 2008
Keywords: View Abstract
Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during last decade [review].Eur Cytokine Netw. 1996;7:93-124
Date Published: April 1996
Keywords: lymphotoxin, receptors, tumor necrosis factor (TNF) View Abstract
Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis.Br J Dermatol.
Date Published: April 2007
Keywords: View Abstract
Ahmad K, Roger S. Development of Crohn disease in a patient on etanercept for psoriasis.Br J Dermatol. 2007
Date Published: June 2007
Keywords: View Abstract
Ahmadi A, Barikbin B, Naseri M, et al. The effect of HESA-A on psoriasis vulgaris.J Drugs Dermatol. 2008;7:559-61
Date Published: June 2008
Keywords: View Abstract
Akhyani M, Ehsani AH, Robati RM, et al. The lipid profile in psoriasis: a controlled studyJ Eur Acad Dermatol Venereol. 2007
Date Published: June 2007
Keywords: View Abstract
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic reviewJ Rheumatol. 2008;35:1354-8
Date Published: July 2008
Keywords: View Abstract
Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy: a regional survey.J Rheumatol. 1993;20:1121-1125
Date Published: July 1993
Keywords: adverse effects, dose-response, methotrexate, pancytopenia, psoriasis, psoriatic arthritis, rheumatoid arthritis View Abstract
Alcaide AJ, Barrera MV, Habicheyn S, et al. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection.J Eur Acad Dermatol Venereol. 2008:[Epub ahead of print]
Date Published: March 2008
Keywords: View Abstract
Dehnavi R, de Roos A, Rabelink TJ, et al. Elevated CRP levels are associated with increased carotid atherosclerosis independent of visceral obesity.Atherosclerosis. 2008 Feb 18. [Epub ahead of print]
Date Published: February 2008
Keywords: View Abstract
Allanore Y, Kahan A, Sellam J, et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis.Clin Chim Acta. 2005;[Epub ahead of print].
Date Published: September 2005
Keywords: arthritis, atherogenic index, cholesterol, C-reactive protein, cytokines, inflammation, infliximab, metabolism, refractory, rheumatoid arthritis, serum, TNF-alfa, tumor necrosis factor (TNF) View Abstract
Al-Salem IH. Striking and rapid improvement of plaque psoriasis with infliximab: a report of two cases.Dermatology. 2003;207:54-56.
Date Published: January 2003
Keywords: administration, dermatologic agents, dosage, dose-response, follow-up studies, infliximab, intravenous, methotrexate, monoclonal antibodies, psoriasis, psoriatic arthritis, tumor necrosis factor (TNF)
Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis.Scand J Rheumatol. 2008;37:155-7
Date Published: March 2008
Keywords: View Abstract
Altobelli E, Petrocelli R, Marziliano C, et al. Family history of psoriasis and age at disease onset in Italian patients with psoriasis.Br J Dermatol. 2007;156:1400-1
Date Published: June 2007
Keywords: View Abstract
Al-Za'abi AM, Ghazarian D, Greenberg GR, et al. Eruptive tufted angiomas in a patient with Crohn's disease.J Clin Pathol. 2005;58:214-216.
Date Published: February 2005
Keywords: angioblastoma, Crohn's disease, gastrointestinal agents, hemangioma, immunosuppression, infliximab, intravenous, lesions, monoclonal antibodies, neoplasms, skin, skin neoplasms, tufted angioma View Abstract
Amital H, Ingber A, Rubinow A. Infliximab-induced remission of extensive plaque psoriasis.Isr Med Assoc J. 2003;5:827-828.
Date Published: November 2003
Keywords: administration, combination therapy, dermatologic agents, dosage, infliximab, intravenous, methotrexate, monoclonal antibodies, oral, psoriasis, remission View Abstract
Ammoury A, El Sayed F, Dhaybi R, et al. Palmoplantar pustulosis should not be considered as a variant of psoriasis.J Eur Acad Dermatol Venereol. 2008;22:392-3
Date Published: March 2008
Keywords: View Abstract
Anandacoomarasamy A, Kannangara S, Barnsley L. Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis.Intern Med J. 2005;35:638-640.
Date Published: October 2005
Keywords: arthritis, infliximab, rheumatoid arthritis, vasculitis View Abstract
Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).Arthritis Rheum. 2005;52:1227-1236
Date Published: April 2005
Keywords: ACR, antirheumatic agents, dactylitis, dermatologic agents, efficacy, enthesitis, infliximab, intravenous, monoclonal antibodies, PASI, psoriasis, psoriatic arthritis View Abstract
Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).J Rheumatol. 2008;35:869-76
Date Published: May 2008
Keywords: View Abstract
REGISTER NOW
